Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus pomalidomide in relapsed/refractory AL amyloidosis
2019-001962-13Phase 2Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab and pomalidomide in light-chain amyloidosis, sponsored by IRCCS San Matteo Foundation. Primary endpoint: Hematologic response rate (CR + VGPR) at completion of 6 cycles. Started Oct 2020; status: terminated.
02
Drugs
daratumumabpomalidomide
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2019-001962-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001962-13.